NO20062635L - Pentafluorsulfanyl-benzoylguanidiner, produksjonsmetode, deres anvendelse som medikamenter eller diagnostiserende midler og medikamenter inneholdende disse - Google Patents

Pentafluorsulfanyl-benzoylguanidiner, produksjonsmetode, deres anvendelse som medikamenter eller diagnostiserende midler og medikamenter inneholdende disse

Info

Publication number
NO20062635L
NO20062635L NO20062635A NO20062635A NO20062635L NO 20062635 L NO20062635 L NO 20062635L NO 20062635 A NO20062635 A NO 20062635A NO 20062635 A NO20062635 A NO 20062635A NO 20062635 L NO20062635 L NO 20062635L
Authority
NO
Norway
Prior art keywords
pentafluorosulfanyl
drugs
benzoylguanidines
production
diagnostic agents
Prior art date
Application number
NO20062635A
Other languages
English (en)
Inventor
Heinz-Werner Kleemann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20062635L publication Critical patent/NO20062635L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)

Abstract

Det beskrives pentafluorsulfanylbenzoylguanidider med formel (I) der R1 til R4 er som definert i kravene. Forbindelsene er egnet for anvendelse som antiarytmiske medikamenter omfattende kardio-protektive komponenter for profylakse eller terapi av infarkt, i tillegg til behandling av angina pectoris. De inhiberer også preventivt de patofysiologiske evenementer som opptrer under iskemisk indusert trauma og særlig under utløsning av iskemisk indusert kardial arytmi.
NO20062635A 2003-11-13 2006-06-08 Pentafluorsulfanyl-benzoylguanidiner, produksjonsmetode, deres anvendelse som medikamenter eller diagnostiserende midler og medikamenter inneholdende disse NO20062635L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10353202A DE10353202A1 (de) 2003-11-13 2003-11-13 Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PCT/EP2004/012393 WO2005047239A1 (de) 2003-11-13 2004-11-03 Pentafluorsulfanyl-benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament

Publications (1)

Publication Number Publication Date
NO20062635L true NO20062635L (no) 2006-08-11

Family

ID=34585094

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062635A NO20062635L (no) 2003-11-13 2006-06-08 Pentafluorsulfanyl-benzoylguanidiner, produksjonsmetode, deres anvendelse som medikamenter eller diagnostiserende midler og medikamenter inneholdende disse

Country Status (39)

Country Link
EP (1) EP1685096B1 (no)
JP (1) JP4528304B2 (no)
KR (1) KR101262065B1 (no)
CN (1) CN100445265C (no)
AR (1) AR046620A1 (no)
AT (1) ATE368029T1 (no)
AU (1) AU2004288758B2 (no)
BR (1) BRPI0416487A (no)
CA (1) CA2551057C (no)
CR (1) CR8321A (no)
CY (1) CY1106868T1 (no)
DE (2) DE10353202A1 (no)
DK (1) DK1685096T3 (no)
DO (1) DOP2004001028A (no)
EC (1) ECSP066563A (no)
ES (1) ES2287788T3 (no)
GT (1) GT200400217A (no)
HK (1) HK1095584A1 (no)
HN (1) HN2004000474A (no)
HR (1) HRP20070364T3 (no)
IL (1) IL175237A (no)
JO (1) JO2466B1 (no)
MA (1) MA28161A1 (no)
MY (1) MY144211A (no)
NI (1) NI200600112A (no)
NO (1) NO20062635L (no)
NZ (1) NZ547172A (no)
OA (1) OA13285A (no)
PE (1) PE20051034A1 (no)
PL (1) PL1685096T3 (no)
PT (1) PT1685096E (no)
RS (1) RS50520B (no)
RU (1) RU2380358C2 (no)
TN (1) TNSN06116A1 (no)
TW (1) TWI334411B (no)
UA (1) UA84307C2 (no)
UY (1) UY28616A1 (no)
WO (1) WO2005047239A1 (no)
ZA (1) ZA200602579B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317124B2 (en) * 2003-11-13 2008-01-08 Sanofi-Aventis Deutschland Gmbh Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates
ES2400322T3 (es) 2008-02-05 2013-04-09 Sanofi Derivados de SF5 como inhibidores de PAR-1, su preparación y utilización como medicamento
WO2012094451A1 (en) * 2011-01-06 2012-07-12 Beta Pharma Canada Inc. Novel ureas for the treatment and prevention of cancer
CN106414402A (zh) 2013-11-01 2017-02-15 宇部兴产株式会社 丙烯酰(氧基或氨基)五氟硫烷基苯化合物、其药学可接受的盐及其前药

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097409T3 (es) * 1992-09-22 1997-04-01 Hoechst Ag Benzoilguanidinas, procedimiento para su preparacion, asi como su empleo como antiarritmicos.
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19517848A1 (de) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorhaltige Benzoylguanidine
DE19526381A1 (de) * 1995-07-19 1997-01-23 Hoechst Ag 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19713427A1 (de) * 1997-04-01 1998-10-08 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19950898A1 (de) * 1999-10-22 2001-04-26 Aventis Pharma Gmbh Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10222192A1 (de) * 2002-05-18 2003-11-27 Aventis Pharma Gmbh Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10338554A1 (de) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
MA28161A1 (fr) 2006-09-01
HRP20070364T3 (en) 2008-01-31
JP4528304B2 (ja) 2010-08-18
HK1095584A1 (en) 2007-05-11
EP1685096B1 (de) 2007-07-25
IL175237A (en) 2010-12-30
UA84307C2 (ru) 2008-10-10
AR046620A1 (es) 2005-12-14
RU2006120448A (ru) 2007-12-27
JO2466B1 (en) 2009-01-20
CN100445265C (zh) 2008-12-24
NZ547172A (en) 2009-12-24
MY144211A (en) 2011-08-15
WO2005047239A1 (de) 2005-05-26
TWI334411B (en) 2010-12-11
DE10353202A1 (de) 2005-06-16
PT1685096E (pt) 2007-09-04
CN1878755A (zh) 2006-12-13
AU2004288758A1 (en) 2005-05-26
KR101262065B1 (ko) 2013-05-08
CA2551057C (en) 2012-10-30
RU2380358C2 (ru) 2010-01-27
IL175237A0 (en) 2006-09-05
CA2551057A1 (en) 2005-05-26
TNSN06116A1 (en) 2007-11-15
EP1685096A1 (de) 2006-08-02
JP2007513076A (ja) 2007-05-24
AU2004288758B2 (en) 2011-06-02
DOP2004001028A (es) 2005-05-14
ZA200602579B (en) 2007-06-27
TW200530162A (en) 2005-09-16
NI200600112A (es) 2006-12-12
KR20060122848A (ko) 2006-11-30
BRPI0416487A (pt) 2007-03-27
OA13285A (en) 2007-01-31
HN2004000474A (es) 2009-06-19
ECSP066563A (es) 2006-10-17
ES2287788T3 (es) 2007-12-16
RS50520B (sr) 2010-05-07
PE20051034A1 (es) 2005-12-23
PL1685096T3 (pl) 2007-11-30
DK1685096T3 (da) 2007-10-22
DE502004004460D1 (de) 2007-09-06
CR8321A (es) 2007-09-14
UY28616A1 (es) 2005-06-30
GT200400217A (es) 2005-06-23
CY1106868T1 (el) 2012-09-26
ATE368029T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
NO20051165L (no) Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
DK1706403T3 (da) Imidazo[4,5-c]pyridinforbindelser og fremgangsmåder til antiviral behandling
MY130810A (en) Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their preparation, their use as medicament, and medicament containing them
NO20065946L (no) DPP-IV-inhibitorer
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
MXPA04012965A (es) Inhibidores virales.
NO20050635L (no) Nye tricykliske spiropiperidiner eller spiropyrrolidiner
NO20050828L (no) lndol-3-svovelderivater
NO20073101L (no) Nye pyridinforbindelser
CO5631443A2 (es) Derivados de 7-aril-3,9-diazabiciclo (3.3.1) non-6-eno y su uso como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales
NO20072290L (no) Organiske forbindelser.
JO2357B1 (en) Derivatives of isoandolone, method of preparation and intermediate compounds of this method, use as pharmaceutical compositions
NO20045447L (no) Pentafluorsulfanyl-benzoylguanidiner, fremgangsmate for deres fremstilling, deres anvendelse som legemiddel eller diagnostisk middel samt medikamenter inneholdende disse
NO20062635L (no) Pentafluorsulfanyl-benzoylguanidiner, produksjonsmetode, deres anvendelse som medikamenter eller diagnostiserende midler og medikamenter inneholdende disse
IL188092A0 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
WO2004007478A3 (en) Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use
BR0312701A (pt) Derivados de 3-guanidinocarbonil-1-hete-roaril-indol, processo de preparação, seu uso como medicamentos e composições farmacêuticas os compreendendo
NO20073710L (no) Kjemiske forbindelser
NO20081195L (no) Imidazopyridinderivater som kannabinoidreceptorligander
AR022130A1 (es) Nuevos derivados de arilalcanoilo, los procesos para su preparacion, uso y las composiciones farmaceuticas que los contienen
MY140691A (en) Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
AR026179A1 (es) Benzoilguanidinas heterociclicamente sustituidas, procedimiento para su preparacion, su empleo como medicamentos o medios de diagnostico asi como los medicamentos que las contienen
MY138896A (en) Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
TW200621687A (en) Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them